Antiplatelet effects of MK-852, a platellet fibrinogen receptor antagonist, in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 5, 2000, Pages 496-507

  Greenberg, Howard E ^a   Wissel, Paul ^b,c   Barrett, Jeffrey ^b,d   Barchowsky, Aaron ^a,e   Gould, Robert ^b   Farrell, Daniel ^b   Panebianco, Deborah ^b   Hand, Elizabeth ^b   Gillen, Lisa ^a   Goldberg, Michael R ^b   Bjornsson, Thorir D ^a,f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DUPONT COMPANY   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BLEEDING TIME; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERANCE; HUMAN; MALE; NORMAL HUMAN; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; AREA UNDER CURVE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THIAZOLIDINES; TIME FACTORS;

EID: 0033668639     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009116     Document Type: Article

References (42)

1. Platelet inhibitor agents in cardiovascular disease: An update
2. Platelet activation in unstable coronary disease
3. Marked platelet activation in viva after intravenous streptokinase
4. Biochemical evidence of platelet activation in patients with persistent unstable angina
5. Significance of the angiographic morphology of localized coronary stenoses: Histopathological correlates
6. Plaque fissuring - The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina
7. Unstable angina with fatal outcome, dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
8. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2
9. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia
10. Exposure of platelet fibrinogen receptors by ADP and epinephrine
11. Human platelets possess an inducible and saturable receptor specific for fibrinogen
12. Prostacyclin inhibits mobilization of fibrinogen-binding sites of human ADP- and thrombin-treated platelets
13. Correlation between fibrinogen binding to human platelets and platelet aggregability
14. δ and α chains of human fibrinogen possess sites reactive with human platelet receptors
15. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model
16. Abolition of in viva platelet thrombus formation in primates with monoclonal antibodies to the platelet GP-IIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GP-IIb/IIIa receptor
17. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor
18. Novel antithrombotic drugs in development
19. Novel antithrombotic approaches to coronary artery disease
20. 3, the fibrinogen receptor (43863A)
21. SC-54684A: An orally active inhibitor of platelet aggregation
22. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A
23. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis
24. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
25. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
26. Effects of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist
27. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: Activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists
28. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700, 462, on platelet aggregation and bleeding in guinea pigs and dogs: Evidence that Ro 43-8857 is orally active
29. A monoclonal antibody that recognizes the GP IIb/IIIa antagonist DMP 728
30. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor
31. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa receptor antagonist
32. SC-49992: A potent and specific inhibitor of platelet aggregation
33. Heparin-controlled study of MK-852 in unstable angina
34. An aspirin-controlled study of MK-852 in patients with unstable angina
35. Noncompartmental determination of the steady state volume of distribution for any mode of administration
36. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
37. Ticlopodine in China: Comparative study of the effect of two dose levels on bleeding time and platelet function in healthy volunteers
38. The bleeding time response to aspirin: Identifying hyperresponder